Advanced breast cancer: chemotherapy phase III trials that change a standard-Reference-Cited by-同舟云学术

Advanced breast cancer: chemotherapy phase III trials that change a standard

Published:2007-08 Issue:7 Volume:18 Page:843-859
ISSN:0959-4973
Container-title:Anti-Cancer Drugs
language:en
Short-container-title:

Author:

Estevez Laura G.,Tusquets Ignasi,Muñoz Montse,Adrover Encarnación,Rovira Pedro Sánchez,Seguí Miguel Ángel,Rodríguez César A.,Lescure Álvaro Rodríguez,Ruiz Manuel,Álvarez Isabel,Mata Jesús García

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology (medical),Pharmacology,Oncology

Reference23 articles.

1. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial;Jassem;J Clin Oncol,2001

2. Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01;Langley;J Clin Oncol,2005

3. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European Organization Research and Treatment of Cancer 10961 multicenter phase III trial;Biganzoli;J Clin Oncol,2002

4. Phase III multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer;Bonneterre;Br J Cancer,2004

5. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial;Nabholtz;J Clin Oncol,2003

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Costs and mortality of recurrent versus de novo hormone receptor-positive/HER2- metastatic breast cancer;Journal of Comparative Effectiveness Research;2015-08

2. Tumor-Specific Systemic Treatment in Advanced Breast Cancer – How Long does it Make Sense?;Breast Care;2011

3. Cost-effectiveness analyses of docetaxel versus paclitaxel once weekly in patients with metastatic breast cancer in progression following anthracycline chemotherapy, in Spain;Clinical and Translational Oncology;2010-10

4. Drug Therapy for Breast Cancer;Journal of the Korean Medical Association;2009

5. Role of gemcitabine in metastatic breast cancer patients: A short review;The Breast;2008-06